Serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major depressive disorder.
BACKGROUND
In major depressive disorder, selective serotonin reuptake inhibitors target the serotonin transporter (SERT). Their response rates (30-50%) are modified by SERT promotor polymorphisms (5-HTTLPR).


OBJECTIVE
To quantify the relationship between SERT occupancy and response, and whether 5-HTTLPR is a modifier.


METHODS
Drug-free depressed outpatients (n=49; both sexes; aged 25-55 years), received paroxetine (20 mg/day). We quantified SERT occupancy with iodine-123-labeled 2beta-carbomethoxy-3beta-(4-iodophenyl)-tropane single-photon emission computed tomography imaging at baseline and after 6 weeks; we genotyped 5-HTTLPR (S, L(G), L(A)).


METHODS
percentage decrease in 17-item Hamilton Depression Rating Scale and response (> or =50% decrease of 17-item Hamilton Depression Rating Scale).


RESULTS
A significant positive relationship between SERT occupancy and clinical response existed only in the L(A)/L(A) genotype (P<0.002). Relative to paroxetine serum concentrations maximal midbrain SERT occupancy was numerically higher for L(A)/L(A) compared with other genotypes, but this difference was nonsignificant (P=0.188).


CONCLUSIONS
Higher SERT occupancy is only associated with more clinical improvement in the L(A)/L(A) genotype. We hypothesize that the L(A)/L(A) carriers have a more dynamic serotonergic system, which seems more responsive to selective serotonin reuptake inhibitors. (ISRCTN Trial Register ISRCTN44111488; http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=193).
Ruhé
Henricus G
HG
Department of Psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. H.G.Ruhe@AMC.UvA.NL
Ooteman
Wendy
W
Booij
Jan
J
Michel
Martin C
MC
Moeton
Martina
M
Baas
Frank
F
Schene
Aart H
AH
D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000378:metabolism / Q000627:therapeutic use; D001483:Base Sequence; D017931:DNA Primers / Q000235:genetics; D003865:Major Depressive Disorder / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D004027:Diencephalon / Q000000981:diagnostic imaging / Q000378:metabolism; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D008636:Mesencephalon / Q000000981:diagnostic imaging / Q000378:metabolism; D008875:Middle Aged; D017374:Paroxetine / Q000378:metabolism* / Q000627:therapeutic use*; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D011401:Promoter Regions, Genetic; D050486:Serotonin Plasma Membrane Transport Proteins / Q000235:genetics* / Q000378:metabolism*; D017367:Selective Serotonin Reuptake Inhibitors / Q000378:metabolism / Q000627:therapeutic use; D015899:Tomography, Emission-Computed, Single-Photon
D018687:Antidepressive Agents, Second-Generation; D017931:DNA Primers; D017374:Paroxetine; D050486:Serotonin Plasma Membrane Transport Proteins; D017367:Selective Serotonin Reuptake Inhibitors; C493230:SLC6A4 protein, human